Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
Open Access
- 1 January 2018
- journal article
- letter
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 14 (1), 115-117
- https://doi.org/10.3988/jcn.2018.14.1.115
Abstract
Huh SY, et al. J Clin Neurol. 2018 Jan;14(1):115-117. https://doi.org/10.3988/jcn.2018.14.1.115Keywords
This publication has 9 references indexed in Scilit:
- Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitorsEuropean Journal of Cancer, 2017
- Myasthenia triggered by immune checkpoint inhibitors: New case and literature reviewNeuromuscular Disorders, 2017
- Pembrolizumab-induced myasthenia gravis: A fatal case reportJournal of Oncology Pharmacy Practice, 2017
- Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragmAnnals of Oncology, 2016
- Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumabMuscle & Nerve, 2016
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyEuropean Journal of Cancer, 2016
- Myasthenia gravis exacerbation associated with pembrolizumabMuscle & Nerve, 2016
- Pembrolizumab-induced necrotic myositis in a patient with metastatic melanomaAnnals of Oncology, 2016
- Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancerDrugs of Today, 2015